The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
Melissa M
MM
Ferrara
D000701:Analgesics, Opioid / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use; D002047:Buprenorphine / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use; D017277:Drug Approval; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence*; D054625:Healthcare Disparities / Q000331:legislation & jurisprudence*; D006801:Humans; D007880:Legislation, Drug; D008691:Methadone / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000600:supply & distribution* / Q000627:therapeutic use; D058850:Opiate Substitution Treatment; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D010098:Oxycodone / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D055553:Prescription Drugs; D019966:Substance-Related Disorders / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D055553:Prescription Drugs; D002047:Buprenorphine; D010098:Oxycodone; D008691:Methadone